Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $ABBV?
ABBV29ELEVATEDpharma
Quantitative
Revenue (CY2026Q2): $16.99B (+10.2% YoY)
Net Income (CY2026Q2): $3.61B (+285.2% YoY)
Net Margin (CY2026Q2): 21.3%
Catalysts
Clinical trial milestone: A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination
Clinical trial milestone: A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
Risks
Position-sizing discipline: Conviction ELEVATED (29 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Squeeze unwind: Short interest can compress before retail catches the move — entry timing critical
Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.
Earnings Catalyst
No recent earnings event.
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology.
Not financial advice. Confirm independently before trading.
You came here for ABBV. You found it after it moved, the same way everyone else did.
$99 once — every ticker on this site ranked before the open.
Tier 1 setups touched +2% intraday 49.5% of the time across 329 tracked calls. Baseline for everything else: 40.8%. That is a +8.7 point edge, measured from the NEXT OPEN — the first price you could actually pay, not the prior close. We publish the misses too: https://catalystedgescanner.com/trust/
Click Become a Founding Member below.
Pay $99 once — not monthly, not ever again.
You keep every future release at that price. Tomorrow's ranked list
lands at 3:30 AM ET, before the open.
29 of 30 founding seats left. The price goes up when they are gone.